Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome

Bone Marrow Transplantation

Volumn 43, Issue 11, 2009, Pages 839-843

  De Padua Silva, L ^a   de Lima, M ^a   Kantarjian, H ^a   Faderl, S ^a   Kebriaei, P ^a   Giralt, S ^a   Davisson, J ^a   Garcia Manero, G ^a   Champlin, R ^a   Issa, J P ^a   Ravandi, F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BUSULFAN; CD34 ANTIGEN; FLUDARABINE; MELPHALAN; METHOTREXATE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CELL COUNT; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CYTOGENETICS; DISEASE COURSE; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEART ARRHYTHMIA; HISTOCOMPATIBILITY; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; T CELL DEPLETION; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AZACITIDINE; DISEASE PROGRESSION; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 67549109557     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.400     Document Type: Article

References (17)

1. Schiffer CA. Clinical issues in the management of patients with myelodysplasia. In: Gerwitz AM, Winter JN, Zuckerman K (eds). Hematology, Am Soc Hematol Educ Program, 2006, pp 205-210.
2. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-2440.
3. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 2006; 106: 1794-1803.
4. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465.
5. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-2054.
6. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004; 4: 988-993.
7. Issa JP. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes:dOse, duration, and patient selection. Nat Clin Pract Oncol 2005; 2: 24-29.
8. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP. Methylation profiling in acute myeloid leukemia. Blood 2001; 97 2823-2829.
9. Pinto A, Zagonel V. 5-Aza-2′-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: Past, present and future trends. Leukemia 1993; 7: 51-60.
10. Pinto A, Maio M, Attadia V, Zappacosta S, Cimino R. Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2′-deoxycytidine. Lancet 1984; 2: 867-868.
11. Pinto A, Zagonel V, Attadia V, Bullian PL, Gattei V, Carbone A et al 5-Aza-2′-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant 1989; 4: 28-32.
12. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52-57.
13. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Atein H et al (eds). World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues, 4th edn. International Agency for Research on Cancer (IARC), 2008, 439pp.
14. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C et al A decision analysis of allogeneic bone marrow transplantation for the myelodysplasia syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104: 579-585.
15. Ambs A, Warren JL, Bellizzi KM, Topor M, Haffer SC, Clauser SB. Overview of the SEER - medicare health outcomes survey linked dataset. Health Care Financ Rev 2008 Summer; 29: 5-21.
16. de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukemias: A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000; 110: 620-630.
17. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al Hematopoietic cell transplantation (HCT)-specific comorbidities index: A new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919.